Japan’s FUJIFILM is making some big bets in a small country with a $928 million capital injection into its FUJIFILM Diosynth Biotechnologies, a leading contract development and manufacturing organization (CDMO) for biologics and advanced therapies. Doubling the Danish drug substance production capacity, the investment will also help expand services from assembly and labeling to packaging services. Denmark becomes a global hub for large-scale manufacturing facilities in the bio-CDMO industry. In an ongoing trend, biopharmaceutical companies offload their expensive manufacturing to agile firms that seek to capture market share via technology advancements, process innovation and more compelling economics.
A brief breakdown from TrialSite News as FUJIFILM reacts to the growing market for biopharmaceuticals.
What will this money help pay for?
A doubling of manufacturing production capacity for bulk drug substance with the addition of a further six mammalian cell bioreactors, bringing the total to 12 x 20,000-liter bioreactors by fall 2023. Additionally, the company can expand other services from assembly and labeling to packaging.
Moreover, the funds pay for the addition of the Denmark site’s first fill/finish production line (added by summer 2023), including a fully-automated, cutting-edge system capable of production up to about 35 million units per annum to support large-scale production. Additionally, by 2022, the company will complete a new packaging line equipped with facilities to assemble multiple types of auto-injectors and automatic labeling to meet a broad range of customer needs.
Denmark is an expensive place to live—why would outsourcing of this manufacturing occur there?
Because the technology and talent to run these operations is hard to come by. The old Biogen facility (now FUJIFILM) has growing momentum not to mention that onsite talent, processes, and sophisticated technologies contributing to a growing brand for biotech company business. Below we discuss the “star” brand power of this location.
How long as FUJIFILM had this Danish facility?
Since 2019, when FUJIFLM spent $890 million to acquire Biogen’s manufacturing subsidiary in Denmark for its world-class cGMP capabilities and its experienced talent.
Is demand growing for their biologic drug manufacturing services?
Yes, the executive vice president, general manager of FUJIFILM’s bio-CDMO division, reports robust growth with existing and new clients. Martin Meeson, chief executive officer of FUJIFILM Diosynth Biotechnologies, notes the capital infusion will help the company meet growing demand.
Denmark site brand power
Apparently the advanced capabilities at this Danish site are so good that they were invited to participate as a collaborative partner in the COVID-19 Therapeutics Accelerator, an initiative launched by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard to accelerate the response to the COVID-19 pandemic.
Sales targets for its Danish operation?
The company seeks to triple sales of its biopharmaceutical development and manufacturing business from its baseline today to 200 billion ($1.9b) per year in fiscal 2025.
What percentage marker share does FUJIFILM have in bio-CDMO space?
Currently FUJIFILM has about 13% and it is targeting 20% along with competitor Lonza based in Switzerland.
FUJIFILM Corporation, based in Tokyo Japan, is one of the major operating companies of FUJIFILM Holdings Corporation. The company brings cutting edge solutions to a broad range of global industries by leveraging the depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. The company generates $21 billion in revenues.
FUJIFILM Diosynth Biotechnologies is an industry-leading Biologics Contract Development and Manufacturing Organization (CDMO) with locations in Teesside, UK, RTP, North Carolina, College Station, Texas and Hillerød, Denmark. FUJIFILM Diosynth Biotechnologies has over thirty years of experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures expressed in a wide array of microbial, mammalian, and host/virus systems. The company offers a comprehensive list of services from cell line development using its proprietary pAVEway™ microbial and Apollo™X cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing. FUJIFILM Diosynth Biotechnologies is a partnership between FUJIFILM Corporation and Mitsubishi Corporation.